glp-1 health risks Do The Benefits of Drugs OutWeigh the Negatives? GLP-1 Agonist: The Good, the

Why GLP-1s and Hormone Therapy Work Better Together Heres where it gets exciting: a 2024 study published in Menopause found that postmenopausal women who were on both semaglutide (the brand name for this is Ozempic) and hormone therapy (HT) lost significantly more weight than those on semaglutide alone

For patients experiencing emotional eating, motivational decline, or depressive symptoms, brief booster sessions of established therapies may be useful

Alm disso, a adeso ao tratamento medicamentoso fundamental para a eficcia do manejo do DM2, sendo necessria a orientao contnua e o suporte de uma equipe de sade multiprofissional para garantir que os pacientes sigam corretamente as prescries mdicas (DA SILVA et al., 2020)

Each woman with a GLP-1RA prescription within three years before and up to 90 days after conception was matched to three similar pregnancies where the mother did not use GLP-1RAs

The best available evidence suggests retatrutide can produce major fat-mass reduction and that lean-mass loss, relative to total weight loss, appears similar to other obesity therapies rather than disproportionately worse

What Experts Are Watching Next The medical community is keeping a close eye on several key variables as next-generation obesity medications move through development pipelines: Long-Term Cardiovascular Outcomes: Major trials are underway to confirm that retatrutides multi-agonist profile translates into a lower risk of stroke, heart attack, and cardiovascular death